Attend the FierceBiotech Executive Breakfast at JPM
Join us on January 14th at the Fairmont San Francisco. Register today.
Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.
After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.
The data position Leo to file for approval of the Dupixent rival in atopic dermatitis next year.